https://technical.ly/baltimore/wp-content/themes/national New York firm leads $40M Series A for Baltimore-based Dracen Pharmaceuticals - Technical.ly Baltimore

Business

Mar. 23, 2018 11:14 am

New York firm leads $40M Series A for Baltimore-based Dracen Pharmaceuticals

Deerfield Management Company invested $36 million in the Johns Hopkins spinout as part of the round.

Lab space at Johns Hopkins' FastForward 1812.

(Photo by Stephen Babcock)

A biotech company founded by Johns Hopkins researchers to develop new drugs to fight cancer said this week that it is raising $40 million in Series A funding.

The round for Dracen Pharmaceuticals was led by Deerfield Management Company, a New York–based firm which invested $36 million in the round.

The year-old company is building on discoveries by Johns Hopkins professors Barbara Slusher, Jonathan Powell and Rana Rais, as well as Pavel Majer of the Institute of Organic Chemistry and Biochemistry in Prague.

The research has shown initial effectiveness of “immuno-metabolism.” According to the company, this involves fighting cancer on two fronts at the same time. One element is cancer metabolism, which seeks to stop the energy sources that keep tumors alive. The other is immunotherapy, which involves harnessing the body’s own immune system to fight cancer.

The company is looking to develop a pipeline of drugs that build on this work, and also sees potential to extend to other types of diseases. The funding will help advance that work.

Deerfield’s engagement in our efforts helps bring us closer to an important potential step forward in the treatment of cancer,” Dracen CEO Thomas M. Etsok said in a statement.

It’s just the latest recent sign of interest in work at Johns Hopkins from healthcare-focused Deerfield. Separately, the firm is also backing a joint venture with Johns Hopkins for early stage therapeutic research called Bluefield Innovations. That fund has $65 million available for research work that shows promise toward being commercialized.

It’s one happening among the university’s wider effort to create more companies from research efforts that once again set the nationwide pace in spending.

Advertisement

Organizations: Bio-Rad Laboratories
-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

Maryland companies raised more than $1B in venture funding in 2018

Maryland cybersecurity company Syncurity closes $2M seed round

Baltimore Summer Funding Collaborative issues call for youth-centered program proposals

SPONSORED

Baltimore

Why a modern office matters for Asymmetrik’s growing culture

Baltimore, MD 21201

14 West

Solutions Specialist

Apply Now
Baltimore, MD

SmartLogic

Developer

Apply Now
Baltimore, MD 21201

Agora Financial, an Agora Company

Front End Web Developer

Apply Now

PGDx signs a pair of partnerships as it looks to expand ‘kitted’ cancer tests

JHU spinout WindMIL Therapeutics expands to Philly, adds two new executives

UMB inks second licensing deal with spinout developing cancer treatments

SPONSORED

Baltimore

SmartLogic propels digital transformation aboard Baltimore Water Taxi

Baltimore, MD 21201

Agora Financial

Email Deliverability Specialist

Apply Now
Annapolis Junction, MD

Asymmetrik

FULL-STACK DEVELOPER

Apply Now
Annapolis Junction, MD

Asymmetrik

SOFTWARE ENGINEER

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!